69 participants
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-09-05
- Start Date:
- 2020-06-20
- Completion:
- 2023-11-30
Conditions
- Metastatic Well Differentiated Neuroendocrine Neoplasm
- Neuroendocrine Tumors
Interventions
- DRUG
No Results Yet